CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Bioventures Opportunities G. Yk Sells 850,543 Shares

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 850,543 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $0.11, for a total value of $93,559.73. Following the transaction, the insider now directly owns 20,533,366 shares in the company, valued at $2,258,670.26. This trade represents a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

CERo Therapeutics Stock Down 8.4 %

Shares of NASDAQ:CERO opened at $0.07 on Friday. CERo Therapeutics Holdings, Inc. has a 12-month low of $0.06 and a 12-month high of $12.80. The stock’s 50-day moving average price is $0.13 and its 200-day moving average price is $0.22.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.